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Breast cancer resistance protein [BCRP/ATP-binding cassette subfamily G member 2 (ABCG2)] is a member of the
ATP-binding cassette transporter family. The presence of ABCG2 on the plasma membrane in many kinds of
human cancer cells contributes to multidrug resistance during chemotherapy, and it has been used as the side
population marker for identifying cancer stem cells in lung cancers. We report here that, in addition to
the membranous form, ABCG2 proteins are also found inside the nucleus, where they bind to the E-box of CDH1
(E-cadherin) promoter and regulate transcription of this gene. Increased expression of ABCG2 causes an increase
of E-cadherin and attenuates cell migration, whereas knockdown of ABCG2 downregulates E-cadherin and
enhances cell motility. In mice, xenografted A549 cells that have less ABCG2 are more likely to metastasize from
the subcutaneous inoculation site to the internal organs. However, for the cancer cells that have already entered
the blood circulation, an increased level of ABCG2, and correspondingly increased E-cadherin, may facilitate
circulating cancer cells to colonize at a distant site and form a metastatic tumor. We propose a novel role for
nuclear ABCG2 that functions as a transcription regulator and participates in modulation of cancer metastasis.
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Lung cancer has a high incidence and mortality rate among human
cancers globally [1]. There are many causes of clinical drug resistance
resulting in recurrence and death; some of which may be attributed to
ATP-binding cassette transporter family, such as ATP-binding cassette
subfamily G member 2 (ABCG2) [2,3]. Increased ABCG2 expression
promotes the exclusion of xenobiotics and their metabolites, thus
protecting cancer cells from the toxic effects of the anti-cancer drugs [3,4].
ABCG2 is also used as a marker for cancer stem cells (CSCs) or
cancer-initiating cells in various human cancers, including lung
cancer [5,6]. CSCs represent a minor population of tumor cells with
stem cell properties such as self-renewal and differentiation capacity.
They are thought to be responsible for tumor initiation, propagation,
resistance to chemotherapy, recurrence or regional spread, and distant
metastasis [7]. Several molecular markers such as CD133 or CD44
are used to identify and purify CSCs. ABCG2, for example, has been
shown to confer side population (SP) phenotype [8] to a subset of
cancer cells that possess the features of CSCs [5]. Furthermore, the
expression level of ABCG2 in the primary tumor can be used to
predict prognostic outcome of patients with lung cancer [9,10].
Despite being used for CSC identification and purification, it remains
largely unknown if and how these CSC markers confer CSCs with
carcinogenic, invasive behaviors or other stemness properties.
Like many other CSC surface markers, ABCG2 proteins are thought
to exist on the plasma membrane where they function to exclude
xenobiotics from the cytoplasm. There are some reports describing
possible localizations of ABCG2 on the membranes of mitochondria
[11] or in the perinuclear region [12]. The presence of ABCG2 at these
subcellular compartments is thought to facilitate substrate efflux from
these organelles and therefore from inside the cell. In this report, we
provide experimental evidence that ABCG2 proteins are also present
inside the nucleus. Recently, several other localization studies have also
demonstrated the possible presence of ABCG2 in the nucleus in head
and neck squamous cell carcinoma cells, chorion trophoblasts, and
glioblastoma multiforme cells [13–15]. However, it remains unclear
whether these nuclear ABCG2 proteins are functional, and if so, what
their functions are. We found that nuclear ABCG2 can serve as a
transcription regulator of CDH1, the E-cadherin–encoding gene, and
such transcriptional regulation, together and integrated with other
regulators of epithelial-mesenchymal transition (EMT) or mesenchymal-
epithelial transition (MET) pathways, can modulate multiple steps of
cancer metastatic process.
Materials and Methods
Cells and Cell Culture
HEK-293T and A549 were obtained from the Bioresource Collection
andResearchCenter of Taiwan (Hsinchu, Taiwan).HEK-293T cells were
cultured inDulbecco's modified Eagle's medium supplemented with 10%
FBS (Invitrogen, Carlsbad, CA). A549 cells were cultured in Nutrient
Mixture F-12 Ham supplemented with 10% FBS (Sigma-Aldrich, St
Louis, MO). All cell lines were cultured at 37°C in a humidified
atmosphere of 5% CO2.
Immunofluorescence Staining
Cells were seeded onto glass slides and fixedwith 4%paraformaldehyde,
permeabilized with saponin or Triton X-100, and subsequently incubated
with the monoclonal ABCG2 primary antibodies 5D3 (1:50; Millipore,
Darmstadt, Germany) or BXP21 (1:100; Santa Cruz Biotechnology,Dallas, TX) overnight at 4°C. The 5D3 antibody recognizes an external
epitope of ABCG2, while the BXP-21 antibody was raised against amino
acids 271 to 396 of ABCG2. Samples were then incubated with Alexa
Fluor 488–conjugated goat anti-mouse IgG antibody (Invitrogen), and
cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI;
Sigma-Aldrich). Images were captured using a TCS-SP5 laser confocal
microscope (Leica, Solms, Germany). Images were further digitally
processed for contrast enhancement using Adobe Photoshop.
Extraction of Subcellular Fractions
To examine the subcellular distribution of endogenous ABCG2, cells
were fractionated using the ProteoExtract Subcellular Proteome
Extraction kit (Calbiochem, Darmstadt, Germany) according to the
manufacturer’s instructions. Three fractions (fraction 1, cytosolic
proteins; fraction 2, membrane and membrane organelles; and fraction
3, nuclear proteins) were collected and used for Western blot analysis.
Immunohistochemistry
Lung cancer tissues were collected from Taipei City Hospital
(Taipei, Taiwan) between 2011 and 2012; the experimental
procedures followed the ethical regulations passed by the Institutional
Review Board. We collected a total of 27 lung cancer tissues including
17 adenocarcinomas, 7 squamous cell carcinomas, 2 adenosquamous
carcinomas, and one poorly-differentiated carcinoma. Immunohisto-
chemistry was performed on 4-μm-thick paraffinized lung tissue
specimens; sections were deparaffinized and rehydrated convention-
ally. For antigen retrieval, slides were immersed in Trilogy (Cell
Marque Corp, Rocklin, CA) and boiled for 30 minutes in a pressure
cooker. Endogenous peroxidase was blocked with 0.3% (vol/vol)
H2O2 in methanol for 30 minutes. The slides were incubated with
the primary anti-ABCG2 (BXP-21; Novus Biologicals, Littleton,
CO) antibody overnight at 4°C. Thereafter, the slides were incubated
for 1 hour with a polymer–HRP-labeled secondary antibody (DAKO
EnVision+ System). Diaminobenzidine tetrahydrochloride was used
as a substrate. Next, the slides were counterstained with hematoxylin
and scanned using a ScanScope CS (Aperio Technologies, Vista, CA).
Wound Healing Migration Assay, Transwell Migration, and
Invasion Assay
Confluent cells in culture dishes were scratched with a P1000
pipette tip and then washed several times to remove detached cells.
Scratched cultures were photographed at 0 to 24 hours using an
Olympus CKX31 inverted microscope (Olympus, Tokyo, Japan)
equipped with a digital camera (Nikon, Tokyo, Japan). Cell
migration was monitored by assessing closure of the wound and
analyzed with ImageJ software. Migration was subsequently defined
as the ratio of the open wound area after 0 to 24 hours to the initial
wound area (% wound area = open wound area after different time
points/initial wound area at 0 hour).
Transwell migration assays were performed using 12-well transwell
migration chambers (8-μm pore size; Millipore). Invasion assays were
performed using 24-well BioCoat Matrigel Invasion Chambers with 8-μm
pores (BD Biosciences, San Jose, CA) according to the manufacturer’s
instructions. The detailed description is given in the SupplementaryMethods.
Generation of the Reporter Construct and Luciferase Assay
The pGL3–E-cadherin wild-type and mutant reporter plasmids
were generated by modifying the pXP2–E-cadherin plasmid kindly
provided by Dr. Muh-Hwa Yang [16]. The reporter constructs were
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or control vectors. A plasmid expressing the bacterial β-galactosidase
gene (pCMV-βGal) was co-transfected in each experiment as an
internal control. Cells were harvested after 48 hours of transfection;
luciferase activity was measured in duplicate wells and normalized to
β-galactosidase activity values to determine transfection efficiency.
Experiments were repeated at least three times independently.
Chromatin Immunoprecipitation Assay
To assess the binding of ABCG2 to the E-box region of the CDH1
promoter, chromatin immunoprecipitation (ChIP) was performed using
a ChIP assay kit (Millipore), according to the manufacturer’s protocol.
Polymerase chain reaction (PCR) and quantitative ChIP (qChIP)
reaction generated a 201-bp product from theCDH1 proximal promoter
(−171 to +30) containing three E-box motifs (E1: −80 to −75; E2: −29
to −24, E3: +22 to +27) as described previously [16]. Primer sequences
were given as follows: P1: 5′-TAGAGGGTCACCGCGTCTAT-3′
(forward) and P2: 5′-TCACAGGTGCTTTGCAGTTC-3′ (reverse).
Electrophoretic Mobility Shift Assay
The electrophoretic mobility shift assay (EMSA) protocol wasmodified
from previous reports [16,17]. Nuclear extracts (10 μg) were incubated
with 1.7 × 105 cpm of [γ-32P]-ATP end-labeled double-stranded
oligonucleotides (E3: 5′-CTGCAAAGCACCTGTGAGCT-3′; E1: 5′-
T G T GG C CGGC A GG T G A A C C C T - 3 ′ ; E 2 : 5 ′ -
GGGGCTCACCTGGCTGCA-3′) in 20 μl of binding buffer at 30°C
for 20 minutes. For competition experiments, unlabeled oligonucleotides
were added to the binding reaction mixture, which was placed on ice 20
minutes before addition of the radiolabeled probe. Addition of an antibody
against the indicated protein resulted in the appearance of a supershift or
impeded the protein-DNA binding.
Experimental Mouse Metastasis Model
All mouse experimental procedures were approved by the Ethical
Committee of Animal Experimentation of the National Yang-Ming
University (Taipei, Taiwan). Six- to eight-week-old male nonobese
diabetic-severe combined immunodeficiency (NOD-SCID) mice were
purchased from the National Laboratory Animal Center (Taipei, Taiwan).
Mice were housed under specific pathogen-free, temperature- controlled
conditions. A549 stable cells (ABCG2-overexpressing cells, vector control
cells, shABCG2-knockdown cells, and shGFP-control cells) were injected
subcutaneously (s.c., 1 × 107) into the right side or intravenously (i.v., 1 ×
106) into the tail vein of at least six NOD-SCID mice per condition. The
mice were killed with CO2 at 62 days (s.c. implanted) or after 6 weeks (i.v.
injected). Subcutaneous tumors and lung tissue were surgically excised,
weighed, and photographed. Tumor volume (V) was calculated by using
the formulaV = 1/2 × length × (width)2. The metastatic potential of A549
stable cell lines was evaluated from the number of lung nodules; number of
nodules exceeding 200 was considered as 200.
Colony Formation Assay
A549 stable cells (100 of each type) were suspended in culture
medium and seeded in six-well culture plate, in triplicate. After
culturing for 9 days, cells were fixed and stained with crystal violet,
and viable colonies comprising more than 50 cells were counted.
Statistical Analysis
All data are represented asmeans ± SD. Statistical differences between
two data sets were compared by Student’s t test; non-parametric datawere compared with theMann-WhitneyU test, using GraphPad Prism
software (v5.0, La Jolla, CA). Differences with P values b .05 were
considered statistically significant.
Results
Nuclear Distributions of ABCG2 Proteins
To further understand the subcellular distribution of ABCG2
proteins, we performed immunofluorescence staining on A549
human lung cancer cells using different fixation and permeabilization
protocols (Figure 1A). Cells were fixed with 4% paraformaldehyde
and treated with a relatively mild detergent, saponin; the subsequent
5D3 anti-ABCG2 antibody signals were predominant in the plasma
membrane (white arrows) and cytoplasm (red arrows), the signals of
which were clearly diminished due to Triton X-100 extraction.
Signals of another ABCG2 monoclonal antibody, BXP21, were also
observed virtually completely in the cytoplasm and nucleus
(Figure 1A, red arrows and white arrowheads), with some signals in
the plasma membranes (Figure 1A, white arrows) after saponin
permeabilization. The nuclear pattern of BXP21 staining (Figure 1A,
white arrowheads) was even more pronounced with a speckled
distribution when cells were treated with Triton X-100. Moreover,
the vertical sections in the x-z and y-z planes of confocal images further
confirmed that ABCG2 was localized to the nucleus (Figure S1A).
Irrespective of whether 5D3 or BXP21 antibody was used, the
membrane patterns of ABCG2 staining were sensitive to Triton X-100
extraction. Intriguingly, the ABCG2 signal obtained with the 5D3
antibody, which recognizes an external epitope of the ABCG2 protein,
was not observed in the nucleus, probably because nuclear ABCG2
undergoes a conformational change, resulting in a lack of recognition by
the 5D3 antibody. We speculate that this is the reason why previous
studies did not observe ABCG2 expression in the nucleus.
In addition to the localization study, we used subcellular fractionation
and Western blot analysis experiments to quantify ABCG2 proteins in
different subcellular compartments. As shown in Figure 1B, ABCG2was
not only found in the cytoplasm fraction (Cyto), which was marked by
the presence of Hsp90α, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), or β-tubulin, and the membrane fraction (Memb), which
contained calnexin, but was also present in the nuclear fraction (Nu),
which was enriched for nucleolar protein hNopp140. The longer
exposure time of Figure 1B is shown in Figure S1B.
ABCG2 proteins were also found on the plasma membrane and
inside the nucleus in another human lung cancer cell line CL1/TPT
(Supplementary Methods). Immunofluorescence staining and cell
fractionation studies showed that ABCG2 proteins were present not
only in the cytoplasm and membrane fractions but also in the nuclear
compartment (Figure S2). Note that the membrane form of ABCG2
was more abundant on the cell surface of CL1/TPT cells (Figure S2,
white arrows) than A549 cells, which rendered CL1/TPT cells
robustly resistant to the chemotherapeutic drug topotecan.
We also performed immunohistochemistry studies on clinical lung
cancer tissues (Figure 1C). The ABCG2 expression patterns were
divided into cytoplasmic/membranous pattern and nuclear pattern
(Table S1). All membranous (exemplified by the top panel and inset
in Figure 1C), cytoplasmic, and nuclear forms (exemplified by the
bottom panel and inset in Figure 1C) of ABCG2 were found, at
individually different proportions, in different regions of cancer
tissues or among different patients. Among the 27 samples examined,
14 cases displayed discernible nuclear staining and the proportion of
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ABCG2 localization did not significantly correlate with clinical
diagnosis and prognosis (e.g., stage or survival). On further analysis,
the percentage of nuclear staining cells in each case was found to be1% to 30%. The high (≧10%) and low (b10%) percentage of nuclear
staining cells in each case were categorized according to Table S1. The
late stage (III and IV) patients showed higher proportion in high
percentage of nuclear staining cells compared to early stage (I and II)
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showed lower proportion in low percentage of nuclear staining cells
compared to early stage (I and II) patients (2/5 vs 21/22). Significant
difference was observed between percentage of nuclear staining and
clinical stage, but no significant difference was observed between
percentage of nuclear staining and survival; this is possibly because the
number of our clinical tissues is insufficient (Table S2).
Additional Biologic Activities of ABCG2
To elucidate the effect of ABCG2 expression, we established stable
ABCG2-overexpressing and ABCG2-knockdown A549 clones whose
ABCG2 expression was either overtly activated by overexpression or
silenced by gene knockdown, respectively. SP cells constitute a cell
population that excludes Hoechst dye from inside the cell
(Figure 2A); these cells were selected by the dashed line and
quantified as percentage at upper left corner of each flow analysis
panel. Note that ABCG2-overexpressing cells contained more SP cells
(34.8%) than vector control cells (20.8%) or parental cells (8.2%). In
contrast, ABCG2-knockdown cells had fewer SP cells (1.5%) than
shGFP control cells (10.9%). These results indicated that the
exogenous ABCG2 proteins were functional and that the knockdown
procedures were effective.
To understand how ABCG2 affects other biologic aspects of the
cell, besides functioning as a membrane transporter, we investigated
the general morphology and motility of A549 cells. A549 cells
containing high levels of ABCG2 were more likely to adhere to each
other and typically formed groups of cell clusters, than the parental
cells or vector control cells, when observed under a microscope
(Figure 2B, arrows). In contrast, ABCG2-knockdown A549 cells
(shABCG2) were generally more dispersed throughout the entire
growth substrate than the control cells; they seldom formed
discernible cell clusters.
ABCG2 did not affect the rate of cell growth. Cell proliferation was
comparable among the parental cells, ABCG2-overexpressing, and
the vector control cells, and ABCG2-knockdown and shGFP control
cells (Figure 2C).
We then examined if and how ABCG2 affected cell motility using
both wound-healing (Figure 2, D and E) and transwell assays
(Figure 2F). Since the rate of cell growth was not affected by ABCG2
(Figure 2C), we concluded that the difference observed in this set of
wound-healing experiments was mainly due to the influence of
ABCG2 on cell motility. The sequence of gap closure was exemplified
by the microscopic images taken at representative time points, and the
rate of wound-healing was quantified by the decrease of cell-free areas.
Note that in parental or vector control cells, more than 70% of the
gap had closed by 19 hours after wounding, whereas the gap remained
largely unfilled in ABCG2-overexpressing cells even after 24 hours
(Figure 2D). In contrast, knockdown of ABCG2 significantly
increased cell movement (Figure 2E). As the initial wound area of
parental or vector control cells in Figure 2E was larger than that inFigure 1. The localization and expression of endogenous ABCG2 in
paraformaldehydeandpermeabilizedwith saponinor TritonX-100, and the
stained with DAPI (blue). The inset is the zoom-in of the area highlighte
membrane, red arrows indicate the cytoplasm, and white arrowheads in
ABCG2 in A549 cells. Whole cell (WCE, lane 1), cytoplasmic (Cyto, lane 2
prepared fromA549cells andused inWesternblot analysis for thedetecti
β-tubulin were used as cytoplasmic fraction makers; calnexin was used
Immunocytochemistry of lung cancer tissues showing significant ABCG
(top panel, inset) and nuclear ABCG2 staining (bottom panel, inset) in difFigure 2D, the gap had closed only 40% to 50% at 24 hours after
wounding. However, the rate of gap closure in shABCG2 cells was
markedly faster than that in parental or shGFP control cells.
Furthermore, in a series of transwell migration assays, the amount
of cells migrating to the opposite side of the transwell membrane was
examined and quantified under microscopy. ABCG2-overexpressing
cells exhibited a 60% decrease in transwell migration, compared to
the control cells, whereas the ABCG2-knockdown cells demonstrated
a 20% increase relative to the control (Figure 2F).
Expression Level of ABCG2 Is Correlated with Genes Related
to Cell Adhesion and Motility
ABCG2-modulated genes were identified from co-expressed genes
in an expression microarray. ABCG2 expression levels were controlled
by ABCG2 overexpression (ABCG2), knockdown (shABCG2), or
control vectors (Vec-ctrl or shGFP) in three independent experiments.
The average ABCG2 expression levels of each treatment are shown in
Figure S3. ABCG2-overexpressing cells had the highest expression
level, while shABCG2-knockdown cells showed the lowest expression
level, and both controls (Vec-ctrl and shGFP) had similar and
intermediate expression levels. We identified highly co-expressed
genes according to Pearson correlation coefficient between test probe
and ABCG2 (209735_at).
The top 100 positively/negatively correlated probes (Table S3)
were selected and represented 135 genes. We then performed gene
ontology (GO) analysis on the gene list by using the online software
DAVID [18]. A total of 41 enriched GO terms was highlighted at the
default threshold, including the terms cell adhesion, growth
regulation, cell development, cellular response to stress, intracellular
transporter, and so on (Table S4). In the term list, cell adhesion
(GO:0007155, P b .05) was the most frequently annotated function
(13/135 genes), consistent with previous cell morphologic observa-
tions that reported that compact cell clusters are found in ABCG2-
overexpressing cells (Figure 2B). Among the 13 genes related to cell
adhesion (data not shown), E-cadherin (CDH1), a key cell-cell
adhesion gene, was found to correlate strongly with ABCG2 (r N 0.9,
P b 5 ×10−5, Figure 3A, left). E-cadherin level is a hallmark in EMT
or MET (reverse EMT) regulation [19]. We also observed that the
mesenchymal marker, N-cadherin (CDH2), had a negative correla-
tion with ABCG2 (r b −0.6, P b .05, Figure 3A, right). This implies
that ABCG2-overexpressing cells retained the phenotype of epithelial
cells by increasing CDH1 and decreasing CDH2. Co-expression of
CDH1 and ABCG2 at mRNA and protein levels were also confirmed
using quantitative reverse transcription (QRT)–PCR (Figure 3, B
and C, and S2C) and Western blot analysis (Figure 3D), respectively.
These results suggest that ABCG2 modulates E-cadherin expression
in A549 and CL1/TPT cells.
Furthermore, we also investigated other epithelial markers,
claudin-1 and ZO-1, and the mesenchymal markers, N-cadherin
and vimentin. When ABCG2 was knocked down, both claudin-1 andA549 cells and lung cancer tissues. (A) A549 cells were fixed with
nstainedwith5D3orBXP21anti-ABCG2antibody (green).Nucleiwere
d with white dash line square box. White arrows indicate the plasma
dicate nuclear signals. Scale bar, 20 μm. (B) Subcellular distribution of
), membranous (Memb, lane 3), and nuclear (Nu, lane 4) extracts were
onofABCG2, usingBXP21anti-ABCG2antibody.Hsp90α, GAPDH, and
as a membrane marker, and hNopp140 was as a nuclear marker. (C)
2 expression in the cytoplasm/membrane, without nuclear expression
ferent squamous cell carcinoma specimens. Scale bar, 50 μm.
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however, no perceptible changes in these markers were observed in
ABCG2-overexpressing cells (Figure 3D). The vimentin levels
remained unchanged in ABCG2 knockdown and overexpressing
cells. These findings indicated that ABCG2 may be partially involved
in EMT or MET regulation, particularly in E-cadherin modulation.ABCG2 Is Involved in Transcriptional Regulation of CDH1
ABCG2 overexpression enhances E-cadherin expression as well
as increased nuclear ABCG2 expression (Figure S4A, left). The
ratio of nuclear/cytoplasmic (N/C) ABCG2 protein levels in ABCG2-
overexpressing cells was also increased (Figure S4A, right), whereas
the nuclear ABCG2 or ratio of N/C ABCG2 protein levels was
Figure 3. ABCG2 affects expression of EMT or MET markers in A549 cells. (A) The ABCG2 expression levels of four A549 stable cell lines
(Vec-ctrl, ABCG2, shGFP, or shABCG2) in microarray experiments. (Left) Expression levels of ABCG2 (X-axis) and CDH1 (Y-axis) show a
strong positive correlation in microarray experiments. (Right) Expression levels of ABCG2 (X-axis) and CDH2 (Y-axis) were negatively
correlated. (B and C) mRNA levels of ABCG2 and CDH1 were measured by QRT-PCR. ABCG2 and CDH1 levels had increased five- and
four-fold in ABCG2-overexpressing cells, respectively. Both genes were decreased three-fold in ABCG2-knockdown cells. Average fold
changes (n= 3) are shown in the bar chart; **P b .01. (D) Western blot analysis of ABCG2 and EMTmarkers in A549 stable cells. Epithelial
markers (E): E-cadherin, claudin-1, and zona occludens (ZO-1); mesenchymal markers (M): N-cadherin and vimentin. β-Tubulin was used
as a loading control. The number at the bottom of each column is the fold change of quantitative protein level normalized to β-tubulin
compared with the control.
Neoplasia Vol. 17, No. 3, 2015 Nuclear ABCG2 modulates CDH1 expression Liang et al. 271decreased in the shABCG2 cells (Figure S4B). We hypothesized that
nuclear ABCG2 could regulate CDH1 transcription by binding to
the CDH1 promoter and thereby regulate E-cadherin expression and
inhibit cell migration. Three E-box motif sequences, CANNTG (E1,
E2, and E3), were identified in the proximal (−147 to +60 base pairs)
promoter region of CDH1 [16]. We therefore generated a reporterFigure 2. ABCG2 affects SP percentage, cell morphology, and m
identification of SP cells in A549 parental, vector control (Vec-ctrl), AB
and ABCG2-knockdown (shABCG2) cells. The SP cell gating area, trea
disappearance of SP cells after treatment with fumitremorgin C are in
cell morphology in parental or stable A549 cells (Vec-ctrl, ABCG2, shG
(C) Comparison of cell growth in parental or stable A549 cells (Vec-ctrl,
in tissue culture plates for 5 days. After the indicated times, viable ce
SD from three independent replicates. (D and E) Wound-healing m
shGFP, and shABCG2). (Left) Photos of wound-healing assay at differe
Values are expressed as percentage of the initial wound area. Scale
shABCG2 cells through uncoated transwell membranes. After 12 h
Representative photographs of transwell membranes showing stain
migratory ability of the indicated cells is displayed in the bottom panel
Scale bar, 100 μm. *P b .05, **P b .01, and ***P b .001.construct containing the E-box wild-type (CAGGTG) or mutant
(ACTTCA) motif of the CDH1 promoter and tested its activation by
ABCG2 (Figure 4A). An increase in wild-type CDH1 promoter
activity was observed in ABCG2-overexpressing cells, while Snail, a
negative regulator of CDH1, clearly suppressed the promoter activity.
Mutation of all three E-boxes abolished the activation by ABCG2 andotility in A549 cells. (A) Hoechst staining and flow cytometric
CG2-overexpressing (ABCG2), shRNA knockdown control (shGFP),
tment of cells with the ABCG2 inhibitor, fumitremorgin C, and the
dicated in the lower right quadrant of each panel. (B) Comparison of
FP, and shABCG2). Arrows indicate cell clusters. Scale bar, 50 μm.
ABCG2, shGFP, and shABCG2). Equal number of cells was cultured
lls were counted after trypan blue staining. Error bars represent the
igration assay in parental and stable A549 cells (Vec-ctrl, ABCG2,
nt time points. (Right) Relative wound area at different time points.
bar, 100 μm. (F) Migration of A549–Vec-ctrl, ABCG2, shGFP, and
ours, the migrated cells were fixed, stained, and photographed.
ed migrated cells in motility experiments (top panel). The relative
. Values shown are means ± SD of three independent experiments.
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Western blot analysis confirmed the expression of ABCG2 and Snail
in wild-type and mutant reporter experiments (Figure 4B, bottom).
Furthermore, ABCG2 upregulated the promoter activity of CDH1 in
a dose-dependent manner (Figure 4C).
We further investigated the interaction between CDH1 promoter
and ABCG2 by ChIP analyses in ABCG2-overexpressing cells. The
presence of the CDH1 promoter in the precipitated complex wasdetermined by PCR amplification, using primers specific for a 201-bp
segment of the proximal portion of the CDH1 promoter (Figure 4D).
This PCR amplicon, containing the E-box motif, was increased in the
sample precipitated with the BXP21 anti-ABCG2 antibody (Figure 4D,
lane 5) compared with the no-antibody control (Figure 4D, lane 2) and
mouse IgG control (Figure 4D, lane 3). qChIP demonstrated a two-
fold increase in the binding of ABCG2 to the CDH1 promoter, as
compared with the mouse IgG control (Figure 4D, bottom).
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bind to the CDH1 E-box motif. ABCG2-binding activity increased
after incubation of nuclear extracts from ABCG2-overexpressing cells
with the labeled E3 box-containing oligonucleotide (Figure 4E, lane
2), and ABCG2-binding activity was specifically competed by 1- or
50-fold unlabeled E3-box oligonucleotides (Figure 4E, lanes 3 and
4). Moreover, use of the BXP21 anti-ABCG2 antibody in the binding
reaction markedly reduced the level of the binding complex
(Figure 4E, lane 5), while no detectable change was observed with
anti-Snail antibody (Figure 4E, lane 6), indicating that the ABCG2
antibody recognizes ABCG2 protein epitope that also contains
ABCG2 protein-DNA binding region. This antibody impedes
ABCG2 protein binding to DNA, so the supershift band was not
observed. Similar results were observed when the E1- or E2-box
oligonucleotide was used for EMSA (data not shown). Thus, these
results demonstrated that ABCG2 activated CDH1 transcription by
binding to the E-boxes of the promoter.
ABCG2 Attenuates Invasiveness but Promotes Colonization of
Circulating Cancer Cells
We next investigated the impact of ABCG2 on tumor growth
and the metastatic ability of four A549 stable cell lines using a
mouse xenotransplantation assay. ABCG2-overexpressing, ABCG2-
knockdown, and their control cells were injected s.c. or i.v. into
NOD-SCID mice. The subcutaneous tumor volumes in the four
groups were not significantly different after 62 days (Figure 5A, left).
To determine the impact of ABCG2 on distant metastases after the
formation of the primary subcutaneous tumors, we performed a
detailed survey in the four groups of mice after sacrifice. One
lung nodule was identified in one of eight mice in the ABCG2-
overexpressing group; six lung nodules were found in one of six mice
in the vector control group (Figure 5A, middle, arrowhead); three
mice in the shABCG2 group showed metastasis [two mice had five
and eight lung nodules, respectively, and one mouse had one colon
nodule (Figure 5A, left, #, and right, arrowhead)]; and no metastases
were observed in the shGFP group (Figure 5A). Although there was a
higher frequency (3/9; 30%) of metastasis in mice injected
with shABCG2 cells compared to those injected with the shGFP
control (0/8; 0%) or the other two groups (ABCG2: 1/8; 12.5%,
Vec-ctrl: 1/6; 16.7%), there was no correlation between tumor
volume and metastasis frequency. These data imply that knockdownFigure 4. ABCG2 enhances CDH1 transcription by binding to the E-b
promoter region of the wild-type (WT) or E-box–mutated (MT) CDH1. T
boxes. (B) Promoter activity assay in HEK-293T cells transfected with
cells were normalized to that in control cells transfected with the emp
the expression of ABCG2 and Snail in cells transfected with various co
and A: pFlag-ABCG2. (C) ABCG2 upregulated the promoter activity o
increasing amounts of pFlag-ABCG2 expression vector, as indicated
experiments. *P b .05, ***P b .001. (D) Top: Schematic representati
(arrowhead). P1 and P2 specifically amplified a 201-bp fragment conta
ChIP-PCR gel image. Fragmented chromatin was incubated either wit
3), anti-polymerase II antibody (pol II, lane 4), or anti-ABCG2 antibody
amplify a 201-bp fragment in A549 ABCG2-overexpressing cells. Pol II
total DNA input (positive control), whereas (–) Ctrl (lane 6) represent
chromatin enrichment indicated by QRT-PCR data, as compared
overexpressing cells. Values shown are the means ± SD from three in
region of the CDH1 promoter using EMSAs. Lane 1: no protein extr
binding of nuclear proteins with the probe. Incubation of the labeled
presence of 1-fold (lane 3) or 50-fold (lane 4) of unlabeled E3-box oligo
appearance of one specific band (lanes 2, 3, and 6). Addition of the an
(lane 5, open arrowhead); Snail antibody was used as a control (laneof ABCG2 promoted invasion of lung or colon tissue. Similarly,
ABCG2-knockdown cells had a higher invasion capacity in the in
vitro invasion assay (Figure 5B). The shABCG2 cells increased their
invasion ability two-fold, while ABCG2-overexpressing cells de-
creased their invasion ability compared to their control cells. All of
these findings indicated that knockdown of ABCG2 increased
invasive ability and conferred distant metastases.
Simultaneously, we also determined the capacity for colonization
in circulating cancer cells by i.v. injection, bypassing the initial steps
of metastasis. We observed and quantified the number of lung
nodules at 6 weeks after i.v. injection using four A549 stable cell lines
(Figure 6, A and B). Nodules produced by ABCG2-overexpressing
cells became confluent on the surface of the lung tissue. The median
number of lung nodules in the recipients of ABCG2-overexpressing
cells was 183 (range: 105-200, N = 9), vector control cells was 33
(range: 7-68, N = 9), ABCG2-knockdown cells was 82 (range: 21-
150, N = 9), and shGFP control cells was 23 (range: 6-38, N = 9).
ABCG2-overexpressing cells had a greater ability to colonize the
lungs than Vec-ctrl (P b .0001) or shABCG2 (P b .0001) cells in vivo
(Figure 6B). Moreover, ABCG2-overexpressing cells had a greater
ability to form colonies in vitro than did the other three groups
(Figure 6C). Although we observed that the colonization ability
of ABCG2-knockdown cells was far lower than that of ABCG2-
overexpressing cells, it remained higher than that of shGFP control
cells in vitro and in vivo. Because the shABCG2 cells have a lower E-
cadherin level (Figure 3, C and D) and higher motility (Figure 2F)
than shGFP control cells, shABCG2 cells may favor localized
migration and cause more lung nodules or greater colony number
than shGFP control cells. These results demonstrated that ABCG2
overexpression decreases invasiveness but promotes lung colonization.
The study implies that the epithelial-type cells in circulation favor to
colonize in the late stage of the metastatic process.
Discussion
We report here that, in addition to the known transport functions on
the plasma membrane, ABCG2 is also present inside the nucleus
where it plays a novel role in modulating CDH1 transcription, similar
to the previous report that the epidermal growth factor receptor
(EGFR) can translocate to nucleus and serve as a transcription factor
to regulate ABCG2 expression [20]. In Figure 7, most ABCG2
proteins synthesized are translocated to the plasma membrane ①,oxes of the CDH1 promoter. (A) Schematic representation of the
SS, transcription start site. E1, E2, and E3 indicate the location of E-
various constructs (top). The promoter luciferase activities of these
ty vectors (pcDNA3 or pFlag-CMV). Western blot analysis confirmed
nstructs. C: pcDNA3 vector, S: pcDNA3-Snail, F: pFlag-CMV vector,
f CDH1 in a dose-dependent manner. Cells were transfected with
. Values shown are means ± SD from at least three independent
on of the promoter region of CDH1 and P1 and P2 paired primers
ining the E-box region of CDH1 in ChIP-PCR or qChIP. Middle panel:
hout antibodies (no Ab, lane 2), with anti-IgG isotype antibody (lane
(lane 5) and was then subjected to PCR using P1 and P2 primers to
was used as control for the ChIP experiment. Lane 1 represents the
s the negative control subjected to PCR. Bottom: Fold change in
with anti-ABCG2 antibody and isotype IgG in A549 ABCG2-
dependent experiments. *P b .05. (E) ABCG2 binds to the E-box (E3)
act. Competition assays were performed to test the specificity of
E3-box oligonucleotides with nuclear extracts alone (lane 2), in the
nucleotides, is shown. Protein-DNA interactions are denoted by the
ti-ABCG2 antibody results in impediment to protein-DNA interaction
6).
Figure 5. ABCG2 attenuates invasiveness in vivo and in vitro. (A) The volume of subcutaneous tumors following injection of 1 × 107
ABCG2-overexpressing, Vec-ctrl, shABCG2, or shGFP stable cells into NOD-SCID mice. The horizontal line indicates the mean of tumor
volume. Red circles indicate mice showing metastasis; # indicates a mouse possessing a colon metastatic nodule. The fraction of mice
developing metastases (MF) in individual groups is represented above. Middle and right representative image of metastatic nodules
(arrowhead) is in lung or colon tissue in different mice, respectively. (B) Invasive ability of A549–Vec-ctrl, ABCG2, shGFP, and shABCG2
cells was examined using Matrigel-coated transwells. After 65 hours, the migrated cells were fixed, stained, and photographed.
Representative images of a transwell insert showing stained invasive cells (top panel). The relative invasive ability of the indicated cells is
displayed in the bottom panel. Values shown are means ± SD from three independent experiments. Scale bar, 100 μm. *P b .05.
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by doing so, confer the cell with SP phenotype. Our localization and
cellular fractionation studies (Figure 1), and functional data
(Figure 4), showed an unexpected distribution of ABCG2 inside
the nucleus ②. The ABCG2-shuttling mechanism between the
plasma membrane and cytoplasm has been investigated. Xie et al.
demonstrated that Pim-1 phosphorylates ABCG2 at Thr362 and
thereby enables its translocation to the cell surface [21]. Moreover,
the phosphatidylinositol-3-kinase (PI3K)-AKT signaling pathway
could regulate ABCG2 translocation from the plasma membrane to
intracellular compartments and could affect efflux activity and SP
[22–24]. In addition, Huang et al. demonstrated that activated Akt
could phosphorylate EGFR and facilitate increased nuclear EGFR
that act as transcription factors to mediate ABCG2 expression ingefitinib resistance cells [20]. Whether AKT and/or Pim-1 activity
modulate ABCG2 shuttling between the cytoplasm and nucleus
requires further investigation. Although ABCG2 lacks the conven-
tional nuclear localization signal (NLS) for import into the nucleus,
ABCG2 contains four lysine residues at positions 357 to 360, which
may act as a putative NLS through interaction with specific receptors
at nuclear pores [15]. It is also possible that ABCG2 is co-transported
into the nucleus by binding to other nuclear or accessory molecules.
Moreover, the EMSA results (Figure 4E) indicated that the specific
binding complex was obstructed by the BXP21 anti-ABCG2
antibody that recognizes the intracellular region (271-396 amino
acid [aa]), which contains the four lysine residues of the putative NLS.
We speculate that this intracellular region (271-396 amino acid [aa])
of ABCG2 may be involved in DNA binding so the supershift band
Figure 6. ABCG2 promotes lung colonization in vivo and in vitro. (A and B) Images of lung tissues and quantification of lung nodules per
mouse at 6 weeks after tail vein injection. The number of lung nodules in mice injected i.v. with 1 × 106 of stable A549 cells (Vec-ctrl,
ABCG2, shGFP, or shABCG2). The horizontal line indicates the median of lung nodules. Scale bar, 2.5 mm. Each dot represents a single
mouse. Student’s t test was used to compare the average number of events per group. **P b .01, ***P b .001. (C) Colony formation assay
of A549 stable cells. Colonies larger than 50 cells were counted. Bottom: Representative images of colonies. Data represents means ±
SD from three independent experiments. *P b .05, **P b .01 by Student’s t test.
Neoplasia Vol. 17, No. 3, 2015 Nuclear ABCG2 modulates CDH1 expression Liang et al. 275was not observed. We are generating several truncated fragments of
ABCG2 and will be using them to verify their cellular distribution. In
future, we will confirm the region of the ABCG2 sequence that is
responsible for nuclear translocation or DNA binding.
In this study, we have verified that ABCG2 is present in the
nucleus of A549 cells, CL1/TPT lung cancer cells, and clinical tissues
(Figures 1 and S2). Additionally, it is interesting that ABCB1,
another ATP-binding cassette transporter, was also previously
demonstrated to locate to the nucleus [25]. Moreover, some studies
have shown that ABCG2 is located in the nucleus in different cell
types, by immunohistochemistry, immunofluorescence, or fraction-
ation experiments [13–15]. These studies all indicate that nuclear
ABCG2 plays an important role in efflux of substrates from the
nuclear compartment. However, these reports did not discuss the
molecular mechanism by which nuclear ABCG2 may affect gene
regulation. In our studies, we not only demonstrated that ABCG2
localizes to the nucleus but also evaluated the molecular mechanisms
involving nuclear ABCG2 in A549 cells. Our immunofluorescence
analysis employed different degrees of permeabilization and different
antibodies (5D3 and BXP21) to further confirm ABCG2 nuclear
localization (Figure 1). Different signal patterns were observed, due to
recognition of different regions of ABCG2. It is a possible thatconformational changes, rather than alternative splicing, are involved
in nuclear ABCG2, because Western blot analysis of cellular fractions
showed that the molecular weight of nuclear ABCG2 is equal to that
of membrane ABCG2 (Figure 1B).
After entering the nucleus, ABCG2 can bind to the E-box promoter
region ofCDH1 and upregulate E-cadherin transcription③. Several well-
known transcription factors bind to the CDH1 promoter and participate
in the control of E-cadherin expression, such as AP-2 and WT-1 bind to
GC-rich region to activate transcription [26,27], and Snail, Slug, SIP1, and
Twist1 bind to the E-box element to repress gene expression [28–32]. E-
box elements were thought to play a critical negative regulatory role in
CDH1 transcription. A breakthrough finding in our study was that
nuclear ABCG2 positively regulated CDH1 expression through E-box
elements of the promoter. We do not yet know if and how ABCG2
interacts and/or coordinates with these transcription factors to regulate E-
cadherin expression in the cancer cells. Nuclear ABCG2 may act as a
competitor against these repressors by binding to E-box element ofCDH1
promoter and decreasing E-cadherin repression. The dynamic interplay
between these well-known transcription factors and ABCG2 on the
CDH1 promoter remains elusive and needs to be unraveled.
E-cadherin is a well-established tumor invasion suppressor [33].
Complex and dynamic transcription regulation is the major mechanism
Figure 7. Proposed metastasis model summarizing the role played by nuclear ABCG2 in upregulating CDH1 transcription and trending
MET progression in this study. ABCG2 localizes to the nucleus and activates CDH1 transcription by binding to promoter region (Top)②③.
The Twist1, Snail, Slug, SIP1, and so on participates in EMT and MET progression by regulating the CDH1 transcription. ABCG2
overexpression causes increased E-cadherin and promotes tumor cell colonization, and subsequently form macrometastases (bottom).
See Discussion section for detailed description. ECM: extracellular matrix.
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progression [19]. E-cadherin plays a pivotal role in many steps during
cancer metastasis, especially those involved in primary tumor invasion
(i.e., penetration of the carcinoma cells through the basement
membrane), entering and leaving the blood stream (intravasation-
circulation-extravasation), and then the formation of ametastatic tumor
(colonization) at a distant site (Figure 7, bottom). Extensive studies have
made it clear that decreased expression of E-cadherin, due to
suppression of CDH1 by transcription repressors, is advantageous for
EMT of the cancer cells to undergo invasion, intravasation, circulation,
and extravasation progression [28–32,34]. However, for migrating
cancer cells to form a metastatic tumor at a distant site, cells need to
settle, recolonize, and grow when high expression of E-cadherin in the
cancer cells can promoteMETprogression [35,36]. Recent studies have
shown that silencing of one repressor (such as SIP1, ZEB1, or Twist1)
could upregulate E-cadherin expression that may play a critical role intumor colonization [37–39]. How ABCG2 is involved in metastatic
progression is currently unclear. In our study, we found that not only
does nuclear ABCG2 positively regulate E-cadherin expression and
enhance metastatic colonization, but overexpressed ABCG2 can also
cause lowering of Snail and SIP1 expression in A549 cells (data not
shown). In addition, ABCG2 may negatively regulate the CDH2
expression that could contribute to the metastatic process (Figure 3, A,
right, and D). Thus, we observed most numerous lung nodules in
xenografted mice, after i.v. injection of ABCG2-overexpressing cells.
Several lines of evidence have indicated that ABCG2 plays a crucial
role in protecting stem cells from death, cytotoxic substrates, and
maintained homeostasis under stress condition or undifferentiated state
[40–42]. In our study, ABCG2-overexpressing cells contained more SP
cells with an epithelial phenotype (Figure 2) and were demonstrated to
have a higher lung metastatic colonization in the mouse model
(Figure 6), suggesting that some SP cells, a CSC-enriched population,
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Recent studies supporting our findings have shown that highly
metastatic CSCs express a strong epithelial gene profile and that
epithelial-type cells promote tumor colonization and proliferation
[43,44]. MET was demonstrated to be essential for efficient metastatic
colonization [45,46] and generation of induced pluripotent stem cells
[47,48]. Additionally, Chang et al. demonstrated that connective tissue
growth factor induces the MET process and stem-like properties,
promoting local progression and reducing invasiveness in head and neck
squamous cell carcinoma [49]. However, both reports demonstrated that
ABCG2-knockdown decreased cell migration and invasion in glioma
stem cells by decreasing matrix metalloproteinase (MMP)-9 or MMP2/9
activity [50,51]. Nevertheless, our studies did not find significant difference
in MMP-9 levels among four A549 stable cells (data not shown).
Collectively, these findings demonstrated that ABCG2 locates to the
nucleus and binds to the CDH1 promoter and then positively regulates
E-cadherin expression in lung cancer cells. Additionally, ABCG2 could
affect cell migration and tumor colonization in vitro and in the
xenografted mouse model. Further analyses would be necessary to
clarify the mechanism of ABCG2 shuttling among the membrane,
cytosol, and nucleus. Changing the localization of ABCG2 from
membrane to nucleus could be theoretically more effective for
improving chemotherapy resistance and suppressing tumor cells with
metastatic potential. Our results suggest that ABCG2 has dual
functional activities, either as a transporter on the plasma membrane
to exclude xenobiotics or as a transcriptional factor in the nucleus to
regulate gene expressions, such as E-cadherin. It is interesting to note
that the nuclear function of ABCG2 can contribute to modulation of
tumor metastasis. Targeting ABCG2 as an anti-cancer treatment may
thus be beneficial for the prevention of both drug resistance and/or
cancer metastasis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.01.004.
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